Trials / Unknown
UnknownNCT03423992
Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
A Pilot Study to Evaluate the Safety and Efficacy of Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas Based on the Expression of Tumor Specific/Associated Antigens
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A pilot study to determine the safety and efficacy of chimeric antigen receptor T cell (autologous T cells transduced with a lentiviral vector expressing chimeric antigen receptor with or without anti-PDL1 antibody) personalized immunotherapy for patients with recurrent malignant gliomas based on the expression of tumor specific/associated antigens (EGFRVIII, IL13Rα2, Her-2, EphA2, CD133, GD2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | chimeric antigen receptor T cells | chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively |
Timeline
- Start date
- 2018-03-02
- Primary completion
- 2023-01-30
- Completion
- 2023-01-30
- First posted
- 2018-02-06
- Last updated
- 2021-06-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03423992. Inclusion in this directory is not an endorsement.